Communiqués MindMaze Therapeutics Holding SA

Actions

RLF

CH1251125998

Recherche biotechnologique et médicale

Temps Différé Swiss Exchange 11:08:52 08/09/2026			Varia. 5j.	Varia. 1 janv.
0,1636 ^CHF	+0,62%		-7,67%	-91,39%

27/08	Bourse Zurich: les indices finissent en rouge avant Jackson Hole	AW
27/08	Mindmaze table sur 200 millions de recettes dans les cinq ans	AW

Communiqués

01/09	MindMaze Therapeutics to Present at Upcoming Investor and Industry Conferences	EQ
27/08	MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update	EQ
12/08	MindMaze Therapeutics Appoints Prof. John W. Krakauer as Strategic Advisor	EQ
10/08	MindMaze Therapeutics Completes Organizational Simplification and Provides Update on Neuro.io Equity Financing	EQ
09/07	MindMaze Therapeutics Supports University of Pittsburgh Study on a Combination Approach to Stroke Recovery, Pairing Spinal Cord Stimulation with High-Dose, High-Intensity Neurotherapy	EQ
01/07	MindMaze Therapeutics Enrolls First Patients in SwissNeuroRehab Study, Advancing At-Home Reimbursement Strategy in Europe	EQ
25/06	MindMaze Therapeutics Announces Results of Annual General Meeting	EQ
03/06	MindMaze Therapeutics Publishes Invitation to the 2026 Annual General Meeting	PR
03/06	MindMaze Therapeutics Publishes Invitation to the 2026 Annual General Meeting	EQ
03/06	MindMaze Therapeutics : AGM invitation 2026 EN	PU
02/06	MindMaze Therapeutics Announces Non-Core Asset Sale and Organizational Simplification	EQ
26/05	MindMaze Therapeutics Announces CHF 8.0 Million Strategic Equity Financing	EQ
12/05	MindMaze Therapeutics and Vibra Healthcare Sign Definitive Channel Partnership Agreement to Scale Advanced Neurotherapeutics Across the U.S.	EQ
30/04	MindMaze Therapeutics and Vibra Healthcare Announce Go-to-Market Partnership to Expand Commercial Footprint of Precision Neurotherapeutics in the U.S.	EQ
15/04	MindMaze Therapeutics Publishes 2025 Annual Report and Corporate Update	EQ
31/03	MindMaze Therapeutics and Vibra Healthcare Announce Breakthrough RWE Results in High-Dose, High-Intensity Neurorehabilitation	EQ
19/03	MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank	AQ
19/03	MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank	EQ
19/03	MindMaze Therapeutics : Announces Initiation of Coverage by Baader Bank	PU
12/03	MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale	BU
12/03	MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale	EQ
12/03	MindMaze Therapeutics : Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale	PU
03/03	MindMaze Therapeutics Provides Corporate Update and Publishes March 2026 Investor Presentation	EQ
03/03	MindMaze Therapeutics : investor presentation – March 2026	PU
23/12	MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics	EQ